Bicara Therapeutics, Inc.

Biopharma financing during the third quarter of 2024 totaled $17bn from 207 deals. Of those, 54 reached $100m or more. The follow-on public offering (FOPO) category made up the made up most (34%) of t

Stock market listings were back on the upswing last quarter, with the eight biotechs floating on Western exchanges raising a total of $1.1bn. In fact, there seems to have been a bit of a rush: three c

BioAge Labs, Inc. switched the development focus for its lead drug candidate, the small molecule apelin receptor (APJ) agonist azelaprag, from age-related muscle loss to prevention of muscle loss in

MBX Biosciences, Inc. , Bicara Therapeutics Inc. and Zenas BioPharma Inc. launched initial public offerings in the US late on 12 September that priced in the middle or at the top of proposed price